Patents by Inventor Sruthi Ravindranathan

Sruthi Ravindranathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11850263
    Abstract: This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: December 26, 2023
    Assignee: Emory University
    Inventors: Edmund Waller, Susan Thomas, Rebecca Pankove, Sruthi Ravindranathan, David Francis
  • Publication number: 20230190865
    Abstract: This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.
    Type: Application
    Filed: October 17, 2022
    Publication date: June 22, 2023
    Inventors: Edmund K. Waller, Rebecca Pankove, Susan Thomas, Sruthi Ravindranathan
  • Patent number: 11471506
    Abstract: This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 18, 2022
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Edmund K. Waller, Rebecca Pankove, Susan Thomas, Sruthi Ravindranathan
  • Publication number: 20220002372
    Abstract: This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 6, 2022
    Inventors: Edmund K. WALLER, Yiwen LI, Sruthi RAVINDRANATHAN, Jian-Ming LI
  • Publication number: 20210046152
    Abstract: This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.
    Type: Application
    Filed: April 24, 2019
    Publication date: February 18, 2021
    Inventors: Edmund K. Waller, Yiwen Li, Giacomo Waller, Rebecca Pankove, Susan Thomas, Sruthi Ravindranathan
  • Publication number: 20200297767
    Abstract: This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.
    Type: Application
    Filed: November 9, 2018
    Publication date: September 24, 2020
    Inventors: Edmund Waller, Susan Thomas, Rebecca Pankove, Sruthi Ravindranathan, David Francis